NEW YORK (GenomeWeb) – Israeli firm Sight Diagnostics is hoping to capture a piece of the $35 billion complete blood count market with the launch of its OLO point-of-care diagnostics system in Europe and other non-US countries.
360Dx Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.